Prime time for drug eluting balloons in SFA interventions?

Area of Science:

• Vascular Surgery
• Interventional Cardiology
• Biomedical Engineering

Background:

• Peripheral arterial disease (PAD) frequently impacts the femoropopliteal arteries.
• Current endovascular treatments for femoropopliteal PAD have limitations in long-term patency and clinical efficacy.
• Advancements in device technology have not fully resolved the challenges in this vascular bed.

Purpose of the Study:

• To evaluate the efficacy and safety of drug-coated balloons (DCBs) for femoropopliteal arterial disease.
• To compare DCB treatment outcomes against established endovascular methods.
• To validate early promising results from initial DCB trials through larger studies.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials (RCTs).
• Inclusion of studies comparing DCBs with standard percutaneous transluminal angioplasty (PTA) or other endovascular interventions.
• Assessment of primary endpoints including primary patency rates and clinical success.

Main Results:

• Drug-coated balloons demonstrated significantly improved primary patency rates compared to standard PTA in femoropopliteal lesions.
• Clinical outcomes, such as freedom from restenosis and need for reintervention, were favorably affected by DCB use.
• Large-scale RCTs confirmed the encouraging findings from earlier first-in-man trials, establishing DCBs as a viable option.

Conclusions:

• Drug-coated balloon technology represents a significant advancement in the endovascular treatment of femoropopliteal peripheral arterial disease.
• DCBs offer a superior alternative for achieving long-term patency and improving clinical benefit in this patient population.
• Further research should focus on long-term outcomes and patient selection for DCB therapy.